The Biomanufacturing Program, (BioMAN), is a collaborative research and educational program in biotherapeutic manufacturing. The objective of this program is to develop new knowledge, science, technologies and strategies that advance the manufacture and global delivery of high quality biopharmaceuticals. BioMAN activities bring together thought leaders from industry, the government/FDA and academia and involve faculty from across the Schools of Science, Engineering and Management at MIT
Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)
The mission of the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) is to develop a comprehensive understanding of adventitious agents encountered in biomanufacturing, the sources of such agents, and a systematic, risk-based analysis of the most effective strategies and technologies to prevent contamination.
NEW Drug Development ParaDIGmS (NEWDIGS)
The New Drug Development Paradigms program (NEWDIGS) focuses on transforming the current global pharmaceutical innovation ecosystem to more reliably and sustainably deliver new, better, affordable drugs to the right patients faster. System re-engineering projects are designed and executed with input from industry; regulators from US, Europe, Singapore, and Canada; payers and health technology assessment officials; providers, patients, and academic researchers from MIT, Harvard and other leading academic institutions.
Completed Research Projects:
Economics of Stratified Medicine
Development and Validation of Tools To Enhance Decision-making Related to “Stratified Medicine”
Strategic Allocation of Global Clinical Trials
Advancing the Strategic Decision Making Process Behind the Selection of Where to Place Patient Recruitment Sites
Enhancing the Productivity of Collaborative Innovation
Comparative Analysis of Established Bioclusters in San Diego, Singapore, and Boston